Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Rental Lab-Style R&D Hub “iPark Kobe” to Open in KBIC
April 2, 2025
- GE Healthcare Fully Acquires Nihon Medi-Physics
April 1, 2025
- Ono Pairs Up with Reborna to Discover CNS Disease Drugs
April 1, 2025
- Chugai CEO’s Pay Tops 400 Million Yen in 2024: Securities Report
April 1, 2025
- Sawai to Pick Up Sumitomo Pharma’s Digital Healthcare Unit
April 1, 2025
- Santen’s Myopia Drug Recommended for European Approval
April 1, 2025
- Otsuka Files IgA Nephropathy Drug Sibeprenlimab in US
April 1, 2025
- Specialist Sees Promise in Bispecific Engagers for MM Therapy
March 31, 2025
- Hematologist Praises Benefit of Fixed-Duration FL Treatment with Lunsumio
March 31, 2025
- Japan Approves Tablet Form of Chugai’s SMA Med Evrysdi
March 31, 2025
- Nippon Shinyaku Files BPDCN Drug in Japan
March 31, 2025
- Eisai Hands Over Rights to Pariet in China to CBC Group
March 31, 2025
- Kaken’s Onychomycosis Drug Scores Nod in Italy
March 31, 2025
- Sawai to Take Over Warfarin from Eisai in Japan
March 28, 2025
- Kaken Closes US$103 Million Acquisition of Aadi Subsidiary
March 28, 2025
- Takeda Seeks Pediatric Nod for cTTP Drug Adzynma in Japan
March 28, 2025
- Xocova Filed for Post-Exposure Prophylaxis for COVID-19 in Japan
March 28, 2025
- Kyushu University Offshoot Eyes US Nod for Repositioned ROP Drug Candidate
March 27, 2025
- Mochida Files Actemra Biosimilar in Japan
March 27, 2025
- J&J Submits Information Disclosure Requests to Japan Govt over Off-Year Revision
March 26, 2025
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…